Bladder Cancer Clinical Trial
A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer
Summary
This is a first-in-human, multicenter, Phase 1/1b, 3-part, double-blind study of ZH9 in patients with recurrent NMIBC who are eligible for intravesical therapy. In Part 1, the safety, tolerability, and pharmacology of ZH9 IVI will be evaluated in a single ascending dose (SAD) patient cohort. In Part 2, the safety, tolerability, and pharmacology of ZH9 oral prime followed by ZH9 IVI will be evaluated in 2 patient cohorts at the doses and schedule established in Part 1. In Part 3, the safety, pharmacology, and clinical efficacy of ZH9 will be further evaluated in 2 expansion cohorts of patients with recurrent intermediate- and high-risk NMIBC.
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years
Histologically documented recurrence of NMIBC
BCG unresponsive (BCG naïve patients may be enrolled if they have received at least 1 line of adequate intravesical standard of care (SOC) treatment and are either not candidates for BCG or do not have access to BCG (e.g., BCG shortage))
Eastern Cooperative Oncology Group Performance Status 0-1
Adequate organ and marrow function
Highly effective contraception if risk of conception exists.
A female participant is eligible if not pregnant, not breastfeeding, not a woman of childbearing potential (WOCBP) or is a WOCBP that uses highly effective contraception.
Exclusion Criteria:
Received treatment with any local or systemic antineoplastic therapy within 3 weeks or 5× the plasma half-life prior to first dose of ZH9
Major surgery or radiation within the 3 weeks prior to Screening (TURBT is not considered major surgery)
Concurrent urinary tract infection or history of clinically significant polyuria
Symptoms consistent with typhoid
Evidence of infection within 2 weeks of the first dose of ZH9
Significant 12-lead electrocardiogram abnormalities
History of malignancy within the previous 12 months
History of allogeneic tissue/solid organ transplant
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
Hanover Maryland, 21076, United States More Info
Principal Investigator
Myrtle Beach South Carolina, 29572, United States More Info
Principal Investigator
San Antonio Texas, 78229, United States More Info
Principal Investigator
How clear is this clinincal trial information?